{"transactions":[{"id":710571,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-13T20:05:31.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."}],"balance_after":0,"derivative":{"exercise_price":0.87,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001628280-26-048010","document":"wk-form4_1783973127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048010/wk-form4_1783973127.xml","form_type":"4"}},{"id":710570,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-13T20:05:31.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."}],"balance_after":0,"derivative":{"exercise_price":2.25,"expiration_date":"2034-05-23","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001628280-26-048010","document":"wk-form4_1783973127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048010/wk-form4_1783973127.xml","form_type":"4"}},{"id":710569,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-13T20:05:31.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an \"in-the-money option\") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR."}],"balance_after":0,"derivative":{"exercise_price":1.37,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001628280-26-048010","document":"wk-form4_1783973127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048010/wk-form4_1783973127.xml","form_type":"4"}},{"id":710568,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T20:05:31.000Z","date":"2026-07-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":164472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation (\"Parent\") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"MergerCo\"), pursuant to which, on July 13, 2026 (the \"Effective Time\"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the \"per share cash consideration\"), and (b) one contractual contingent value right per share (each, a \"CVR\" and, together with the per share cash consideration, the \"merger consideration\"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 79,873 restricted stock units (each, a \"RSU\"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the \"per share cash consideration\"), and (b) one contractual contingent value right per share (each, a \"CVR\" and, together with the per share cash consideration, the \"merger consideration\"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Includes 79,873 restricted stock units (each, a \"RSU\"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-048010","document":"wk-form4_1783973127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026048010/wk-form4_1783973127.xml","form_type":"4"}},{"id":733959,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-17T20:47:05.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":63481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":235036,"source":{"system":"sec-edgar","filing":"0001193125-26-274301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000119312526274301/ownership.xml","form_type":"4"}},{"id":756930,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T20:23:56.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":79873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026."}],"balance_after":164472,"source":{"system":"sec-edgar","filing":"0001628280-26-039526","document":"wk-form4_1780345434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039526/wk-form4_1780345434.xml","form_type":"4"}},{"id":768655,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-21T20:32:04.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":34200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027."},{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027."}],"balance_after":34200,"derivative":{"underlying":"Common Stock","underlying_shares":34200},"source":{"system":"sec-edgar","filing":"0001587788-26-000002","document":"wk-form4_1779395521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000158778826000002/wk-form4_1779395521.xml","form_type":"4"}},{"id":768654,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2026-05-21T20:32:04.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":41800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to vest 100% on May 20, 2027."}],"balance_after":41800,"derivative":{"exercise_price":1.23,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":41800},"source":{"system":"sec-edgar","filing":"0001587788-26-000002","document":"wk-form4_1779395521.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000158778826000002/wk-form4_1779395521.xml","form_type":"4"}},{"id":1113220,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-12T20:28:05.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":171555,"source":{"system":"sec-edgar","filing":"0000950170-25-085448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017025085448/ownership.xml","form_type":"4"}},{"id":1127511,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T20:08:22.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025."}],"balance_after":44000,"derivative":{"exercise_price":0.87,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001628280-25-028824","document":"wk-form4_1748894896.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025028824/wk-form4_1748894896.xml","form_type":"4"}},{"id":1127510,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T20:08:22.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025."}],"balance_after":84599,"source":{"system":"sec-edgar","filing":"0001628280-25-028824","document":"wk-form4_1748894896.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025028824/wk-form4_1748894896.xml","form_type":"4"}},{"id":1139368,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-21T20:58:15.000Z","date":"2025-05-21","kind":"exercise","planned":false,"acquired":false,"shares":2167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2167},"source":{"system":"sec-edgar","filing":"0001055726-25-000038","document":"wk-form4_1747861088.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000038/wk-form4_1747861088.xml","form_type":"4"}},{"id":1139367,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-21T20:58:15.000Z","date":"2025-05-21","kind":"exercise","planned":false,"acquired":true,"shares":2167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."}],"balance_after":9209,"source":{"system":"sec-edgar","filing":"0001055726-25-000038","document":"wk-form4_1747861088.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000038/wk-form4_1747861088.xml","form_type":"4"}},{"id":1471952,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-21T20:05:13.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":24311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":126555,"source":{"system":"sec-edgar","filing":"0000950170-24-076213","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000095017024076213/ownership.xml","form_type":"4"}},{"id":1501840,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-24T20:14:36.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024."}],"balance_after":32500,"derivative":{"exercise_price":2.25,"expiration_date":"2034-05-23","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001628280-24-025210","document":"wk-form4_1716581657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024025210/wk-form4_1716581657.xml","form_type":"4"}},{"id":1501839,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T20:14:36.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024."}],"balance_after":51599,"source":{"system":"sec-edgar","filing":"0001628280-24-025210","document":"wk-form4_1716581657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024025210/wk-form4_1716581657.xml","form_type":"4"}},{"id":1505963,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-22T20:51:38.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":2167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025."}],"balance_after":2167,"derivative":{"underlying":"Common Stock","underlying_shares":2167},"source":{"system":"sec-edgar","filing":"0001055726-24-000040","document":"wk-form4_1716411078.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000040/wk-form4_1716411078.xml","form_type":"4"}},{"id":1505962,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2024-05-22T20:51:38.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":2917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to vest 100% on May 21, 2025."}],"balance_after":2917,"derivative":{"exercise_price":10.99,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":2917},"source":{"system":"sec-edgar","filing":"0001055726-24-000040","document":"wk-form4_1716411078.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000040/wk-form4_1716411078.xml","form_type":"4"}},{"id":1514771,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-16T21:11:09.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":false,"shares":2166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2166},"source":{"system":"sec-edgar","filing":"0001055726-24-000032","document":"wk-form4_1715893857.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000032/wk-form4_1715893857.xml","form_type":"4"}},{"id":1514770,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T21:11:09.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":true,"shares":2166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."}],"balance_after":7042,"source":{"system":"sec-edgar","filing":"0001055726-24-000032","document":"wk-form4_1715893857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000032/wk-form4_1715893857.xml","form_type":"4"}},{"id":1846429,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-22T21:31:13.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":102244,"source":{"system":"sec-edgar","filing":"0001209191-23-039143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919123039143/doc4.xml","form_type":"4"}},{"id":1851950,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:06:41.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023."}],"balance_after":21000,"derivative":{"exercise_price":1.37,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001628280-23-022453","document":"wf-form4_168694598491957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023022453/wf-form4_168694598491957.xml","form_type":"4"}},{"id":1851949,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T20:06:41.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":5150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023."}],"balance_after":28599,"source":{"system":"sec-edgar","filing":"0001628280-23-022453","document":"wf-form4_168694598491957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023022453/wf-form4_168694598491957.xml","form_type":"4"}},{"id":1892073,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-16T20:53:27.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 15, 2024."}],"balance_after":26000,"derivative":{"underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001055726-23-000036","document":"wk-form4_1684270397.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000036/wk-form4_1684270397.xml","form_type":"4"}},{"id":1892072,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2023-05-16T20:53:27.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to vest 100% on May 15, 2024."}],"balance_after":35000,"derivative":{"exercise_price":0.77,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001055726-23-000036","document":"wk-form4_1684270397.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000036/wk-form4_1684270397.xml","form_type":"4"}},{"id":1892071,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-16T20:53:27.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001055726-23-000036","document":"wk-form4_1684270397.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000036/wk-form4_1684270397.xml","form_type":"4"}},{"id":1892070,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-16T20:53:27.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":true,"shares":19000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."}],"balance_after":58521,"source":{"system":"sec-edgar","filing":"0001055726-23-000036","document":"wk-form4_1684270397.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000036/wk-form4_1684270397.xml","form_type":"4"}},{"id":2053969,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-01-17T21:05:12.000Z","date":"2023-01-15","kind":"exercise","acquired":false,"shares":4273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4273},"source":{"system":"sec-edgar","filing":"0001055726-23-000001","document":"wf-form4_167398949169166.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000001/wf-form4_167398949169166.xml","form_type":"4"}},{"id":2053968,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T21:05:12.000Z","date":"2023-01-15","kind":"exercise","acquired":true,"shares":4273,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares vested on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"}],"balance_after":39521,"source":{"system":"sec-edgar","filing":"0001055726-23-000001","document":"wf-form4_167398949169166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000001/wf-form4_167398949169166.xml","form_type":"4"}},{"id":2244471,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-03T20:06:36.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":21571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":79894,"source":{"system":"sec-edgar","filing":"0001209191-22-033982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919122033982/doc4.xml","form_type":"4"}},{"id":2253244,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-27T20:15:56.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The awards vest in full on the earlier of (i) May 26, 2023 and (ii) the Issuer's next annual meeting of stockholders following May 26, 2022."}],"balance_after":20000,"derivative":{"exercise_price":5.51,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-015586","document":"wf-form4_165368251000420.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022015586/wf-form4_165368251000420.xml","form_type":"4"}},{"id":2268713,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2022-05-17T20:29:28.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options to vest 100% on May 16, 2023."}],"balance_after":28000,"derivative":{"exercise_price":1.89,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001055726-22-000040","document":"wf-form4_165281934246034.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572622000040/wf-form4_165281934246034.xml","form_type":"4"}},{"id":2268712,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-17T20:29:28.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023."},{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023."}],"balance_after":19000,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001055726-22-000040","document":"wf-form4_165281934246034.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572622000040/wf-form4_165281934246034.xml","form_type":"4"}},{"id":2268711,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-17T20:29:28.000Z","date":"2022-05-13","kind":"exercise","acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001055726-22-000040","document":"wf-form4_165281934246034.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572622000040/wf-form4_165281934246034.xml","form_type":"4"}},{"id":2268710,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T20:29:28.000Z","date":"2022-05-13","kind":"exercise","acquired":true,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022."}],"balance_after":35248,"source":{"system":"sec-edgar","filing":"0001055726-22-000040","document":"wf-form4_165281934246034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572622000040/wf-form4_165281934246034.xml","form_type":"4"}},{"id":2434059,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-01-18T21:06:22.000Z","date":"2022-01-15","kind":"exercise","acquired":false,"shares":4274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"}],"balance_after":4273,"derivative":{"underlying":"Common Stock","underlying_shares":4274},"source":{"system":"sec-edgar","filing":"0001055726-22-000002","document":"wf-form4_164253996843398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572622000002/wf-form4_164253996843398.xml","form_type":"4"}},{"id":2434058,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-18T21:06:22.000Z","date":"2022-01-15","kind":"exercise","acquired":true,"shares":4274,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares vested on January 15, 2022; 4,273 shares will vest on January 15, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both"}],"balance_after":17248,"source":{"system":"sec-edgar","filing":"0001055726-22-000002","document":"wf-form4_164253996843398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572622000002/wf-form4_164253996843398.xml","form_type":"4"}},{"id":2680855,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-06-04T20:19:31.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":22766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year."}],"balance_after":58323,"source":{"system":"sec-edgar","filing":"0001209191-21-038223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121038223/doc4.xml","form_type":"4"}},{"id":2691099,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T20:18:36.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":12376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 27, 2022 and (ii) the Issuer's next annual meeting of stockholders following May 27, 2021."}],"balance_after":23449,"source":{"system":"sec-edgar","filing":"0001628280-21-011359","document":"wf-form4_162223309169622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828021011359/wf-form4_162223309169622.xml","form_type":"4"}},{"id":2710798,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-05-17T20:28:15.000Z","date":"2021-05-14","kind":"exercise","acquired":false,"shares":8700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8700},"source":{"system":"sec-edgar","filing":"0001055726-21-000046","document":"wf-form4_162128327904320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572621000046/wf-form4_162128327904320.xml","form_type":"4"}},{"id":2710797,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-05-17T20:28:15.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2022."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001055726-21-000046","document":"wf-form4_162128327904320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572621000046/wf-form4_162128327904320.xml","form_type":"4"}},{"id":2710796,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2021-05-17T20:28:15.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options to vest 100% on May 13, 2022."}],"balance_after":27000,"derivative":{"exercise_price":6.23,"expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001055726-21-000046","document":"wf-form4_162128327904320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572621000046/wf-form4_162128327904320.xml","form_type":"4"}},{"id":2710795,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T20:28:15.000Z","date":"2021-05-14","kind":"exercise","acquired":true,"shares":8700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 14, 2021."}],"balance_after":12974,"source":{"system":"sec-edgar","filing":"0001055726-21-000046","document":"wf-form4_162128327904320.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572621000046/wf-form4_162128327904320.xml","form_type":"4"}},{"id":2906321,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-01-16T00:24:01.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":4274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."}],"balance_after":8547,"derivative":{"underlying":"Common Stock","underlying_shares":4274},"source":{"system":"sec-edgar","filing":"0001055726-21-000003","document":"wf-form4_161075662594602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572621000003/wf-form4_161075662594602.xml","form_type":"4"}},{"id":2906320,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-16T00:24:01.000Z","date":"2021-01-15","kind":"exercise","acquired":true,"shares":4274,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares vested on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."}],"balance_after":4274,"source":{"system":"sec-edgar","filing":"0001055726-21-000003","document":"wf-form4_161075662594602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572621000003/wf-form4_161075662594602.xml","form_type":"4"}},{"id":2958269,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-12-03T21:34:19.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":10830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding\nthe date of the annual meeting of stockholders for the next calendar year."}],"balance_after":35557,"source":{"system":"sec-edgar","filing":"0001209191-20-061502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120061502/doc4.xml","form_type":"4"}},{"id":2958268,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-12-03T21:34:19.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":24727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in three equal installments on the first three\nanniversaries of the date of grant."}],"balance_after":24727,"source":{"system":"sec-edgar","filing":"0001209191-20-061502","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120061502/doc4.xml","form_type":"4"}},{"id":3130532,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:39:13.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":6106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 28, 2021 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2020."}],"balance_after":11073,"source":{"system":"sec-edgar","filing":"0001179110-20-006716","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911020006716/edgar.xml","form_type":"4"}},{"id":3147664,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-05-15T20:04:47.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":8700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 14, 2021."}],"balance_after":8700,"derivative":{"underlying":"Common Stock","underlying_shares":8700},"source":{"system":"sec-edgar","filing":"0001055726-20-000034","document":"wf-form4_158957306492147.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572620000034/wf-form4_158957306492147.xml","form_type":"4"}},{"id":3147663,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2020-05-15T20:04:47.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":13300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to vest 100% on May 14, 2021."}],"balance_after":13300,"derivative":{"exercise_price":13.65,"expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":13300},"source":{"system":"sec-edgar","filing":"0001055726-20-000034","document":"wf-form4_158957306492147.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572620000034/wf-form4_158957306492147.xml","form_type":"4"}},{"id":3178893,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2020-04-09T16:05:38.000Z","date":"2020-04-08","kind":"disposition_to_issuer","acquired":false,"shares":9291,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person resigned his position as Chairman of the Board of Directors of Aravive, Inc., effective April 8, 2020, resulting in the forfeiture of 9,291 shares of common stock issuable upon the vesting of certain restricted stock units previously granted on December 20, 2017."}],"balance_after":61201,"source":{"system":"sec-edgar","filing":"0000899243-20-010588","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924320010588/doc4.xml","form_type":"4"}},{"id":3309820,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option","published_at":"2020-01-16T21:09:27.000Z","date":"2020-01-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on January 15, 2020; 5,000 shares will vest on January 15, 2021; 5,000 shares will vest on January 15, 2022; 5,000 shares will vest on January 15, 2023."}],"balance_after":20000,"derivative":{"exercise_price":3.35,"expiration_date":"2030-01-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001055726-20-000004","document":"wf-form4_157920894919990.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572620000004/wf-form4_157920894919990.xml","form_type":"4"}},{"id":3309819,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-01-16T21:09:27.000Z","date":"2020-01-15","kind":"grant","acquired":true,"shares":12821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 12,821 restricted stock units is as follows: 4,274 shares will vest on January 15, 2021; 4,274 shares will vest on January 15, 2022; 4,273 shares will vest on January 15, 2023.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."}],"balance_after":12821,"derivative":{"underlying":"Common Stock","underlying_shares":12821},"source":{"system":"sec-edgar","filing":"0001055726-20-000004","document":"wf-form4_157920894919990.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572620000004/wf-form4_157920894919990.xml","form_type":"4"}},{"id":3314343,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-01-09T19:59:53.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":5075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option to purchase shares of common stock of Aravive, Inc. (the \"Company\") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option to purchase shares of common stock of Aravive, Inc. (the \"Company\") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The stock option to purchase shares of common stock of Aravive, Inc. (the \"Company\") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The stock option to purchase shares of common stock of Aravive, Inc. (the \"Company\") vest pro rata on a monthly basis over the next eight months of continuous service commencing February 9, 2020 with full vesting, if not fully vested at such time, on the date of the Company's next annual meeting of stockholders."}],"balance_after":5075,"derivative":{"exercise_price":13.77,"exercise_date":"2020-02-09","expiration_date":"2030-01-08","underlying":"Common stock","underlying_shares":5075},"source":{"system":"sec-edgar","filing":"0000899243-20-000912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924320000912/doc4.xml","form_type":"4"}},{"id":3330889,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-12-26T16:05:46.000Z","date":"2019-12-20","kind":"tax_withholding","acquired":false,"shares":2262,"price":11.67,"value":26397.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant."}],"balance_after":70492,"source":{"system":"sec-edgar","filing":"0000899243-19-030048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319030048/doc4.xml","form_type":"4"}},{"id":3395864,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-08T16:08:04.000Z","date":"2019-10-07","kind":"sale","acquired":false,"shares":4004,"price":6.817,"value":27295.268,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant."}],"balance_after":72754,"source":{"system":"sec-edgar","filing":"0000899243-19-025300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319025300/doc4.xml","form_type":"4"}},{"id":3506246,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-31T20:50:13.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":4967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares vest in full on the earlier of (i) May 29, 2020 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2019."}],"balance_after":4967,"source":{"system":"sec-edgar","filing":"0001179110-19-006914","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911019006914/edgar.xml","form_type":"4"}},{"id":3529279,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-05-13T18:15:42.000Z","date":"2019-05-10","kind":"sale","acquired":false,"shares":1192,"price":6.11,"value":7283.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant."}],"balance_after":76758,"source":{"system":"sec-edgar","filing":"0000899243-19-013333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319013333/doc4.xml","form_type":"4"}},{"id":3617955,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option","published_at":"2019-03-04T16:50:09.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options vest pro rata on a monthly basis over 48 months."}],"balance_after":116000,"derivative":{"exercise_price":5.83,"exercise_date":"2019-03-28","expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0000899243-19-005786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319005786/doc4.xml","form_type":"4"}},{"id":3673651,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-05T19:53:20.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":990,"price":4.14,"value":4098.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant."}],"balance_after":81950,"source":{"system":"sec-edgar","filing":"0000899243-19-002710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319002710/doc4.xml","form_type":"4"}},{"id":3673650,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-05T19:53:20.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":969,"price":4.14,"value":4011.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant."}],"balance_after":82940,"source":{"system":"sec-edgar","filing":"0000899243-19-002710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319002710/doc4.xml","form_type":"4"}},{"id":3673649,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-05T19:53:20.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":204,"price":4.14,"value":844.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units, which were previously reported in Table I following the date of grant."}],"balance_after":83909,"source":{"system":"sec-edgar","filing":"0000899243-19-002710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000089924319002710/doc4.xml","form_type":"4"}},{"id":3718785,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-12-26T20:01:40.000Z","date":"2018-12-21","kind":"sale","acquired":false,"shares":3484,"price":3.224,"value":11232.416,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."}],"balance_after":84113,"source":{"system":"sec-edgar","filing":"0001209191-18-064136","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919118064136/doc4.xml","form_type":"4"}},{"id":3724310,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-12-19T19:59:40.000Z","date":"2018-12-17","kind":"sale","acquired":false,"shares":11247,"price":3.962,"value":44560.614,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares reflects the one-for-six reverse stock split effected by Aravive, Inc. on October 16, 2018."}],"balance_after":87597,"source":{"system":"sec-edgar","filing":"0001209191-18-063590","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919118063590/doc4.xml","form_type":"4"}},{"id":3915345,"issuer":{"id":30796,"kind":"organization","name":"Esperion Therapeutics, Inc.","symbol":"ESPR"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-29T20:34:47.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":18700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in equal monthly installments rounded down to the nearest whole share over the 36 months following May 24, 2018, with the balance of the options vesting on the last monthly vesting date which is the third anniversary of May 24, 2018."}],"balance_after":18700,"derivative":{"exercise_price":37.69,"expiration_date":"2028-05-24","underlying":"Common Stock","underlying_shares":18700},"source":{"system":"sec-edgar","filing":"0001179110-18-007618","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434868/000117911018007618/edgar.xml","form_type":"4"}},{"id":3920059,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-23T17:42:45.000Z","date":"2018-05-22","kind":"sale","acquired":false,"shares":9232,"price":1.5,"value":13848.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."}],"balance_after":593066,"source":{"system":"sec-edgar","filing":"0001209191-18-032687","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919118032687/doc4.xml","form_type":"4"}},{"id":4065652,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-02-12T17:25:01.000Z","date":"2018-02-08","kind":"sale","acquired":false,"shares":14446,"price":1.8,"value":26002.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."}],"balance_after":602298,"source":{"system":"sec-edgar","filing":"0001209191-18-009272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919118009272/doc4.xml","form_type":"4"}},{"id":4122213,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-12-22T17:07:59.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":223000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of Restricted Stock Units that vest as follows:  25% of the shares vest on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021."}],"balance_after":616744,"source":{"system":"sec-edgar","filing":"0001209191-17-067103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117067103/doc4.xml","form_type":"4"}},{"id":4188743,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-10-10T20:15:16.000Z","date":"2017-10-06","kind":"grant","acquired":true,"shares":189000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of Restricted Stock Units that vest as follows:  50% of the shares vest on each of October 6, 2018 and October 6, 2019."}],"balance_after":393744,"source":{"system":"sec-edgar","filing":"0001209191-17-056566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117056566/doc4.xml","form_type":"4"}},{"id":4320336,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-05-15T17:02:55.000Z","date":"2017-05-11","kind":"sale","acquired":false,"shares":9114,"price":17.5,"value":159495.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."}],"balance_after":204744,"source":{"system":"sec-edgar","filing":"0001209191-17-032372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117032372/doc4.xml","form_type":"4"}},{"id":4416893,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-28T19:34:40.000Z","date":"2017-02-27","kind":"exercise","acquired":false,"shares":5166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option become exercisable one year from 12/10/2013; the remainder become exercisable in equal monthly installments over the following three years."}],"balance_after":65828,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":5166},"source":{"system":"sec-edgar","filing":"0001209191-17-015522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117015522/doc4.xml","form_type":"4"}},{"id":4416892,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-28T19:34:40.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":5166,"price":24,"value":123984.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."}],"balance_after":213858,"source":{"system":"sec-edgar","filing":"0001209191-17-015522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117015522/doc4.xml","form_type":"4"}},{"id":4416891,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-28T19:34:40.000Z","date":"2017-02-27","kind":"exercise","acquired":true,"shares":5166,"price":2.53,"value":13069.98,"ownership":{"direct":true},"balance_after":219024,"source":{"system":"sec-edgar","filing":"0001209191-17-015522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117015522/doc4.xml","form_type":"4"}},{"id":4427207,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-23T20:23:32.000Z","date":"2017-02-23","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option become exercisable one year from 12/10/2013; the remainder become exercisable in equal monthly installments over the following three years."}],"balance_after":70994,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-014077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117014077/doc4.xml","form_type":"4"}},{"id":4427206,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-23T20:23:32.000Z","date":"2017-02-21","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option become exercisable one year from 12/10/2013; the remainder become exercisable in equal monthly installments over the following three years."}],"balance_after":78994,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-014077","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117014077/doc4.xml","form_type":"4"}},{"id":4427205,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-23T20:23:32.000Z","date":"2017-02-23","kind":"sale","acquired":false,"shares":8000,"price":20,"value":160000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."}],"balance_after":213858,"source":{"system":"sec-edgar","filing":"0001209191-17-014077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117014077/doc4.xml","form_type":"4"}},{"id":4427204,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-23T20:23:32.000Z","date":"2017-02-23","kind":"exercise","acquired":true,"shares":8000,"price":2.53,"value":20240.0,"ownership":{"direct":true},"balance_after":221858,"source":{"system":"sec-edgar","filing":"0001209191-17-014077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117014077/doc4.xml","form_type":"4"}},{"id":4427203,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-23T20:23:32.000Z","date":"2017-02-21","kind":"sale","acquired":false,"shares":8000,"price":18.5,"value":148000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."}],"balance_after":213858,"source":{"system":"sec-edgar","filing":"0001209191-17-014077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117014077/doc4.xml","form_type":"4"}},{"id":4427202,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-23T20:23:32.000Z","date":"2017-02-21","kind":"exercise","acquired":true,"shares":8000,"price":2.53,"value":20240.0,"ownership":{"direct":true},"balance_after":221858,"source":{"system":"sec-edgar","filing":"0001209191-17-014077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117014077/doc4.xml","form_type":"4"}},{"id":4465975,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-06T17:23:11.000Z","date":"2017-02-03","kind":"sale","acquired":false,"shares":6719,"price":13.69,"value":91983.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $13.35 to $14.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":213858,"source":{"system":"sec-edgar","filing":"0001209191-17-008073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117008073/doc4.xml","form_type":"4"}},{"id":4470786,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-02T20:12:09.000Z","date":"2017-02-01","kind":"exercise","acquired":false,"shares":4166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":86994,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":4166},"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470785,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-02T20:12:09.000Z","date":"2017-02-01","kind":"exercise","acquired":false,"shares":6576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":91160,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":6576},"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470784,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-02T20:12:09.000Z","date":"2017-01-31","kind":"exercise","acquired":false,"shares":10662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully vested."}],"balance_after":97736,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":10662},"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470783,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-02-02","kind":"sale","acquired":false,"shares":6973,"price":13.51,"value":94205.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold at prices ranging from $13.30 to $13.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":220577,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470782,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-02-02","kind":"exercise","acquired":true,"shares":4166,"price":2.53,"value":10539.98,"ownership":{"direct":true},"balance_after":227550,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470781,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-02-01","kind":"sale","acquired":false,"shares":6576,"price":13.95,"value":91735.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold at prices ranging from $13.70 to $14.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":223384,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470780,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-02-01","kind":"exercise","acquired":true,"shares":6576,"price":2.53,"value":16637.28,"ownership":{"direct":true},"balance_after":229960,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470779,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-01-31","kind":"sale","acquired":false,"shares":5940,"price":14.16,"value":84110.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold at prices ranging from $13.70 to $14.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":223384,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470778,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-01-31","kind":"sale","acquired":false,"shares":4722,"price":13.4,"value":63274.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares sold pursuant to 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $12.70 to $13.65.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":229324,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4470777,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-02T20:12:09.000Z","date":"2017-01-31","kind":"exercise","acquired":true,"shares":10662,"price":2.53,"value":26974.86,"ownership":{"direct":true},"balance_after":234046,"source":{"system":"sec-edgar","filing":"0001209191-17-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117007335/doc4.xml","form_type":"4"}},{"id":4475010,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-30","kind":"exercise","acquired":false,"shares":10596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":108398,"derivative":{"exercise_price":2.53,"expiration_date":"2023-12-27","underlying":"Common Stock","underlying_shares":10596},"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4475009,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":144900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/48th of the shares subject to the option become exercisable monthly measured from the date of grant."}],"balance_after":144900,"derivative":{"exercise_price":14.3,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":144900},"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4475008,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-30","kind":"sale","acquired":false,"shares":10596,"price":13.31,"value":141032.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares sold pursuant to 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold at prices ranging from $12.90 to $13.80.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":223384,"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4475007,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-30","kind":"exercise","acquired":true,"shares":10596,"price":2.53,"value":26807.88,"ownership":{"direct":true},"balance_after":233980,"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4475006,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-30","kind":"sale","acquired":false,"shares":6674,"price":13.85,"value":92434.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant."}],"balance_after":223384,"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4475005,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the grant of Restricted Stock Units that vest as follows: 33.33%, 33.33% and 33.34% of the shares subject to the award vest on each of the first, second and third anniversaries of the date of grant, respectively, subject to the officer's continuous service on each applicable vesting date."}],"balance_after":230058,"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4475004,"issuer":{"id":114535,"kind":"organization","name":"Aravive, Inc.","symbol":"ARAV"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-01-31T20:34:38.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":64700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of Restricted Stock Units that vest as follows: 25% of the shares subject to the award vest on each of the first, second, third and fourth anniversaries of the date of grant, respectively, subject to the officer's continuous service on each applicable vesting date."}],"balance_after":220058,"source":{"system":"sec-edgar","filing":"0001209191-17-006522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1513818/000120919117006522/doc4.xml","form_type":"4"}},{"id":4486361,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock","published_at":"2017-01-19T17:20:02.000Z","date":"2017-01-17","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of restricted stock represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of restricted stock vest on 1/17/18."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":4500,"derivative":{"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-17-003119","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465917003119/a4.xml","form_type":"4"}},{"id":4486360,"issuer":{"id":83359,"kind":"organization","name":"MARINUS PHARMACEUTICALS, INC.","symbol":"MRNS"},"owners":[{"id":30802,"kind":"person","name":"Shepard Jay","position":1,"cik":"0001587788","reported_name":"Shepard Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-01-19T17:20:02.000Z","date":"2017-01-17","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase shares of common stock vest in 12 equal monthly installments commencing 1/31/17."}],"balance_after":10500,"derivative":{"exercise_price":1.21,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001104659-17-003119","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465917003119/a4.xml","form_type":"4"}}]}